X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors.

[1]  A. Engelman,et al.  Structural biology of retroviral DNA integration. , 2011, Virology.

[2]  Maxwell D. Cummings,et al.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance , 2010, Proceedings of the National Academy of Sciences.

[3]  Goedele N. Maertens,et al.  The mechanism of retroviral integration through X-ray structures of its key intermediates , 2010, Nature.

[4]  J Polanski,et al.  Quinoline-based antifungals. , 2010, Current medicinal chemistry.

[5]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[6]  J. Polanski,et al.  Investigating biological activity spectrum for novel quinoline analogues 2: hydroxyquinolinecarboxamides with photosynthesis-inhibiting activity. , 2008, Bioorganic & medicinal chemistry.

[7]  J. Polanski,et al.  Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. , 2007, Bioorganic & medicinal chemistry letters.

[8]  B. Fraisse,et al.  Crystal and electronic structures of magnesium(II), copper(II), and mixed magnesium(II)-copper(II) complexes of the quinoline half of styrylquinoline-type HIV-1 integrase inhibitors. , 2007, The journal of physical chemistry. B.

[9]  Gerhard Klebe,et al.  How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase. , 2007, Angewandte Chemie.

[10]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature reviews. Drug discovery.

[11]  J. Polanski,et al.  Fragment Based Approach for the Investigation of HIV-1 Integrase Inhibition , 2007 .

[12]  J. Polanski,et al.  Investigating biological activity spectrum for novel quinoline analogues. , 2007, Bioorganic & medicinal chemistry.

[13]  Uwe Dr Petersen,et al.  Quinolone Antibiotics: The Development of Moxifloxacin , 2006 .

[14]  Hugo Kubinyi,et al.  Privileged Structures and Analogue‐Based Drug Discovery , 2006 .

[15]  J. Polanski,et al.  Antifungal properties of new series of quinoline derivatives. , 2006, Bioorganic & medicinal chemistry.

[16]  Jaroslaw Polanski,et al.  5-Hydroxy-6-Quinaldic Acid as a Novel Molecular Scaffold for HIV-1 Integrase Inhibitors , 2006 .

[17]  J. Polanski,et al.  Intermolecular interactions in the crystal structures of potential HIV-1 integrase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[18]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[19]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[20]  Cunxin Wang,et al.  Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies. , 2004, Acta pharmacologica Sinica.

[21]  C. Vita,et al.  Styrylquinolines, Integrase Inhibitors Acting Prior to Integration: a New Mechanism of Action for Anti-Integrase Agents , 2004, Journal of Virology.

[22]  M. Hassar,et al.  Antileishmanial activity of a new 8-hydroxyquinoline derivative designed 7-[5'-(3'-phenylisoxazolino)methyl]-8-hydroxyquinoline: preliminary study. , 2004, Farmaco.

[23]  Pietro Monforte,et al.  Analysis of the full-length integrase-DNA complex by a modified approach for DNA docking. , 2003, Biochemical and biophysical research communications.

[24]  Johann Gasteiger,et al.  Use of the Kohonen neural network for rapid screening of ex vivo anti-HIV activity of styrylquinolines. , 2002, Journal of medicinal chemistry.

[25]  R. Enriz,et al.  Inhibitors of the fungal cell wall. Synthesis of 4-aryl-4-N-arylamine-1-butenes and related compounds with inhibitory activities on beta(1-3) glucan and chitin synthases. , 2000, Bioorganic & medicinal chemistry.

[26]  M Le Bret,et al.  Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. , 2000, Journal of medicinal chemistry.

[27]  J. Mouscadet,et al.  Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. , 1998, Journal of medicinal chemistry.

[28]  Louis J. Farrugia,et al.  ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI) , 1997 .

[29]  M. Arnold,et al.  Highly Efficient and Practical Syntheses of Lavendamycin Methyl Ester and Related Novel Quinolindiones. , 1996, The Journal of organic chemistry.

[30]  K. Diederichs.  SUPERIMPOSE– a program for the unambiguous structural superposition of spatially related molecules, including macromolecules , 1994 .

[31]  D. Boger,et al.  Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones. , 1987, Journal of medicinal chemistry.

[32]  D. Karnofsky,et al.  Clinical observations on the effects of streptonigrin in patients with neoplastic disease. , 1961, Antibiotics & chemotherapy.

[33]  W. Wilson,et al.  Preliminary observations on the use of streptonigrin as an antitumor agent in human beings. , 1961, Antibiotics & chemotherapy.

[34]  C. Ganellin,et al.  Analogue-based Drug Discovery , 2006 .

[35]  J. Fostel,et al.  Emerging novel antifungal agents. , 2000, Drug discovery today.

[36]  S. Gould,et al.  Structure determination of lavendamycin- a new antitumor antibiotic from streptomyces lavendulae , 1981 .